Glioma virotherapy: Effects of innate immune suppression and increased viral replication capacity

Cancer Research

Volumn 66, Issue 4, 2006, Pages 2314-2319

  Friedman, Avner ^a   Tian, Jianjun Paul ^a   Fulci, Giulia ^b   Chiocca, E Antonio ^a   Wang, Jin ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SIZE; CELL MIGRATION; CONTROLLED STUDY; CYTOLYSIS; DRUG MECHANISM; GENE REPLICATION; GLIOMA; HERPES SIMPLEX VIRUS 1; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; NONHUMAN; ONCOLYTIC VIRUS; PRIORITY JOURNAL; RAT; VIRUS REPLICATION;

ANIMALS; BRAIN NEOPLASMS; CYCLOPHOSPHAMIDE; GLIOMA; HERPESVIRUS 1, HUMAN; IMMUNOSUPPRESSIVE AGENTS; MODELS, BIOLOGICAL; RATS; VIRUS REPLICATION;

EID: 33644547005     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2661     Document Type: Article

References (30)

1. Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an EIB-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004;10:958-66.
2. Csatary LK, Gosztonyi G, Szeberenyi J, et al. MTH-68/ H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 2004;67:83-93.
3. Lorence RM, Pecora AL, Major PP, et al. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther 2003;5:618-24.
4. Papanastassiou V, Rampling R, Fraser M, et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002;9:398-406.
5. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251-66.
6. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma Gene Ther 2000;7:859-66.
7. Hansen AS, Noren O, Sjostrom H, Werdelin O. A mouse aminopeptidase N is a marker for antigen-presenting cells and appears to be co-expressed with major histocompatibility complex class II molecules. Eur J Immunol 1993;23:2358-64.
8. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
9. Ganly I, Kim D, Eckhardt G, et al. A phase I study of ONYX-015, an EiB-attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000;6:798-806.
10. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
11. Mineta T, Rabkin S, Yazaki T, Hunter W, Martuza R. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-43.
12. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific anti-positive prostate cancer cells. Cancer Res 2000;57:2559-63.
13. Coffey MC, Strong JE, Forsyth PA, Lee PWK. Reovirus therapy of tumors with activated Ras pathways. Science 1998;282:1332-4.
14. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002;2:938-50.
15. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther 2003;10:983-90.
16. Aghi M, Chou TC, Suling K, Breakefeld XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/CYP2B1 and ganciclovir/HSV-TK gene therapies. Cancer Res 1999;59:3861-5.
17. Wakimoto H, Fulci G, Tyminski E, Chiocca EA. Altered expression of antiviral cytokines mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 2004;11:214-23.
18. Wu JT, Byrne HM, Kirn DH, Wein LM. Modeling and analysis of a virus that replicates selectively in tumor cells. Bull Math Biol 2001;63:731-68.
19. Wu JT, Kirn DH, Wein LM. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bull Math Biol 2004;66:605-25.
20. Friedman A, Tao Y. Analysis of a model of a virus that replicates selectively in tumor cells. J Math Biol 2003;47:391-423.
21. Abbas AK, Lichtman AH. Cellular and molecular immunology. Philadelphia: Saunders; 2003.
22. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an El-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000;60:6359-66.
23. Nemunaitis J, Cunningham C, Bchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001;8:746-59.
24. Fowler JF. The phantom of tumor treatment-continually rapid proliferation unmasked. Radiother Oncol 1991;22:156-8.
25. Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 2001;81:1930-7.
26. Batchelor GK. An introduction to fluid dynamics. London: Cambridge University Press; 1979.
27. Chaplain M, Kuznetsov V, James Z, Stepanova A. Spatio-temporal dynamics of the immune system response to cancer. In: Horn MA, Simonett G, Webb GF, editors. Mathematical models in medical and health sciences. Nashville: Vanderbilt University Press; 1998. p. 79-97.
28. O'Connell J, Bennett M, O'Sullivan G, Collins J, Shanahan F. The fas counterattack: cancer as a site of immune privilege. Immunol Today 1999;20:46-52.
29. Kusnetzov V, Zhivoglyadov V, Stepanova L. Kinetic approach and estimation of the parameters of cellular interaction between the immune system and a tumour. Arch Immunol Ther Exp (Warsz) 1993;41:21-32.
30. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with β-emitting radionuclides. J Nucl Med 1995;36:1902-9.